Core Insights - The AI Innovation Asia event will take place on December 2nd at The Four Seasons Singapore, focusing on the challenges businesses face in implementing AI for growth and achieving ROI [1][2] - The event will gather 500 executives to discuss practical applications of AI through case studies and panel discussions, providing actionable strategies for scaling AI in Asia [2][3] Event Details - The opening keynote will feature Janil Puthucheary, senior minister of state for the Ministry of Education and the Ministry of Sustainability and the Environment in Singapore [1][2] - The event is sponsored by notable companies including Boston Consulting Group, TikTok, Silverfort, Boomi, Lenovo, and ViSenze [4] Key Themes - The regulatory outlook for firms in Asia, focusing on compliance challenges in a fragmented regulatory ecosystem [4] - Measuring ROI on AI projects to justify spending and ensure profitability [4] - Understanding agentic AI's impact on customer experience and responsible utilization [4] - Addressing the 'black box' dilemma of explainable AI to maintain visibility in AI systems without compromising effectiveness [4]

Core Insights - NetraMark Holdings Inc. has announced a collaboration focused on glioblastoma (GBM) research, utilizing proprietary know-how and access to clinical and biomarker datasets from a leading U.S. academic medical center [1][5] Group 1: Collaboration and Objectives - The collaboration aims to apply NetraAI, the company's explainable AI platform, to identify patient subgroups for developing a therapeutic decision support tool for future GBM trials [2] - Specific objectives include generating insights from longitudinal cerebrospinal fluid (CSF) proteomic datasets and creating NetraPersonas to optimize trial enrichment strategies [4][5] Group 2: Glioblastoma Challenges - Glioblastoma is characterized by a median survival of just 15 months, with less than 7% of patients surviving beyond five years, and clinical trials have a failure rate exceeding 90% due to heterogeneous patient populations and limited predictive biomarkers [3] Group 3: Data Utilization and Analysis - The academic partner will provide expanded longitudinal glioblastoma proteomic datasets generated on the SomaLogic platform, which will be analyzed to identify molecular markers and understand treatment impacts [5][7] - NetraAI's unique focus mechanisms allow for the separation of small datasets into explainable and unexplainable subsets, enhancing the potential for accurate insights and reducing the risk of overfitting [6][8]